

About us

ESGTI AG is an investment company driven by the overriding belief that investing based on ESG principles will deliver equal returns for investors and a better world for all. We combine the risk mitigation of ESG with the power and potential of technology to deliver impact at pace and scale.

We invest in early-stage companies or projects with transformative impact objectives, offering them a platform to successfully scale their business.


Our investment objective

To provide shareholders with long-term capital growth ESGTI AG acquires, holds and sells equity positions in other companies and finances these investments for the main purpose of return from capital appreciations and income from these investments. Equity investments can take the form of a security which has an equity participation feature; the most common forms are common stock, convertible preferred stock, and subordinated debt with conversion privileges or warrants. Net profits generated upon realizations are planned to be re-invested.

Note from our Chairman Andreas Bihrer, March 2023

“As we reach the end of the first quarter we have adjusted our asset fair values to reflect Q1 progress. Our March NAV reflects the collective milestones made by our portfolio assets, the most noticeable of which is the increased valuation of Eko Agro Group following agreements with major actors in the agri-photovoltaic and agricultural sectors, and AltEnergis who assured their asset development as planned during Q1.”

Our portfolio



AgTech & Sustainable Agriculture

EKO AGRO Group

Transformers of agriculture into sustainable and scalable low-environmental impact systems. Extends to agrovoltatics for renewable energy generation.



Life Sciences

BioEleSonic

Specialists in medical devices, with an Acoustic Energy technology platform

Noxogen Therapeutics

Developer of proprietary formulations for the sustained release of nitric oxide

TheraLect

A biotechnology leveraging Lectins

Énielle

Cellular level skincare developer

Rhéon Medical

MedTech specialized in Glaucoma



Clean Technology & Energy

AltEnergis

DeepTech focused on the development and commercialization of innovative energy efficiency IP

Sky Energy


Alternative energy provider with a portfolio of modern wind turbines and solar photovoltaic systems

Investor Information

NAV performance and share price discount

The March NAV per share sits at 6.89, up 6.3% versus February.

FX changes (GBP and EUR) drive 12.8% of this change due to valuations of value major assets in these currencies. The remaining 87.2% are the result of quarterly valuation adjustments for our major assets; some details of which can be found on the following page.



CHE-114.775.734 – VALOR 29829498 – WKN A1409X

Key facts		
Total net assets		CHF 179 million
Total investments		CHF 256 million
Debt-equity ratio		0.43
Advisory fee		0.5% GAV
Incentive fee		10% w/HWM

ESGTI Shares		
ISIN		CH0298294981
Ticker		ESGTI
Exchange		BX Swiss
Current discount		90%

ESGTI Bonds		
ISINs		XS2158598354 / XS2173130746
Issues		CHF 83.3 million / CHF 16.7 million
Type		Asset backed fixed rate certificates
Issuer		Aldburg SA
Coupons		5.75% semi-annual
Exchange		Frankfurt

Figures as of 31st March 2023

Board of Directors

Andreas R Bihrer, Chairman
 Dimitri Dimitriou
 Jessica Kourniaktis
 Kim Marty
 Brunella Pavesi
 Wolfgang H. Werlé
 Hermann A. Wirz

Contact

Address: Rothusstrasse 21
 6331 Hünenberg, Switzerland
 +41 44 366 40 31
 investors@esgti.com

Investment advisor

ESG Engineering & Consulting
 Manage Mind AG

Auditors

PricewaterhouseCoopers

Administrator & NAV

ARIA Fund Services

ESG Advisors & Raters

Sevenbridge
 Inrate AG / Impak

Bank

EFG Bank AG

Key Contributors

March NAV shows a 6.3% increase vs. February, the majority of which is derived from asset level valuation adjustments. Some details are shared below for the major contributors of this change, the calculations of which are aligned with our valuation policy.



AgTech & Sustainable Agriculture

Eko Agro Group has achieved many key milestones in Q1 2023, including preliminary signed agreements with key energy partners and agricultural partners alike within the field of agri-photovoltaic solutions. The scope and progress of plays a substantial role in our March NAV increase.



Life Sciences

Slight NAV adjustment downwards to account for one quarter year of patent life and delayed lead times to market penetration. BioEleSonic continues to explore opportunities for early partnering of BES-1001 alongside fundraising for the clinical study of BES-1001.



Clean Technology & Energy

Development activities for AltEnergis during Q1 2023 remained on-track for all of assets. Consequently, a moderate increase in value is assumed since Q4 2022 in accordance with valuation calculations and it's overall contribution to the March NAV increase is high.

DISCLAIMER: The information contained herein has been prepared for information purposes only as they are at the time of the publication. Nothing contained herein is or shall be deemed to be an offer, or a solicitation of an offer to buy or sell any security or financial instrument or to participate in any trading strategy or to undertake any investment. It is solely based on information from sources believed to be reliable, but the Company, its Directors, the Investment Advisor or the Administrator have not taken any steps to verify the adequacy, accuracy or completeness of any information contained herein. The Company, its Directors, the Investment Advisor nor the Administrator nor any of its respective affiliates, officers, directors, agents and employees make any warranty, express or implied, of any kind whatsoever, and none of these parties shall be liable for any losses, damages, costs or expenses, of every kind and description, relating to the adequacy, accuracy or completeness of any information in this document or the use of this information for any purposes whatsoever. The Company, its Directors, the Investment Manager, the Investment Advisor or the Administrator have no obligation to update or amend the information provided herein, which can change or be changed at any time in the future. All terms and conditions are indicative only and are subject to change without notice. This document has not been approved by any supervisory authority or any authority. With regard to all performance data contained in this document, readers should note the following: past performance is not necessarily indicative of future results.